Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma

Thomas E. Witzig*, Christine A. White, Gregory A. Wiseman, Leo I. Gordon, Christos Emmanouilides, Andrew Raubitschek, Nalini Janakiraman, John Gutheil, Russell J. Schilder, Stewart Spies, Daniel H.S. Silverman, Elizabeth Parker, Antonio J. Grillo-López

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

524 Scopus citations

Fingerprint Dive into the research topics of 'Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20<sup>+</sup> B-cell non-Hodgkin's lymphoma'. Together they form a unique fingerprint.

Medicine & Life Sciences